Interaction between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned

Gastroenterology

Volumn 149, Issue 6, 2015, Pages 1315-1317

  Back, David J ^a   Burger, David M ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DACLATASVIR; LEDIPASVIR; MULTIDRUG RESISTANCE PROTEIN; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; IMIDAZOLE DERIVATIVE;

ADVERSE OUTCOME; ANTIVIRAL THERAPY; BRADYCARDIA; DRUG ABSORPTION; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; ELIMINATION HALF-LIFE; GENETIC PREDISPOSITION; HEART RATE; HEPATITIS C; HUMAN; PRIORITY JOURNAL; ADVERSE EFFECTS; CHEMICALLY INDUCED; DRUG COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; MALE;

AMIODARONE; BRADYCARDIA; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IMIDAZOLES; MALE; SOFOSBUVIR;

EID: 84945587876     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.09.031     Document Type: Editorial

References (11)

1. Anonymous. FDA warns of serious slowing of the heart rate when the antiarrhythmic drug amiodarone us used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug. Available from: www.fda.gov; accessed May 17, 2015.
2. S. Renet, M.-C. Chaumais, T. Antonini, and et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge Gastroenterology 149 2015 1378 1380
3. Anonymous. IMPORTANT DRUG WARNING. Serious and life-threatening cases of symptomatic bradycardia as well as one case of fatal cardiac arrest reported with coadministration of amiodarone with either Harvoni® (ledipasvir and sofosbuvir fixed-dose combination) or with Sovaldi® (sofosbuvir) in combination with another direct acting antiviral. Dear Healthcare Provider letter. Gilead Sciences, March 20, 2015.
4. C.A. Naranjo, U. Busto, E.M. Sellers, and et al. A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 30 1981 239 245
5. H. Van Herendael, and P. Dorian Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia Vasc Health Risk Manag 6 2010 465 472
6. Y. Chen, J. Mao, and C.E. Hop Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone Drug Metab Dispos 43 2015 182 189
7. C.T. de Kanter, J.P. Drenth, J.E. Arends, and et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations Clin Pharmacokinet 53 2014 409 427
8. V. Soriano, and I. Esposito Caution with new oral hepatitis C drugs AIDS Rev 17 2015 121 122
9. K. Robinson, A. Johnston, S. Walker, and et al. The digoxin-amiodarone interaction Cardiovasc Drugs Ther 3 1989 25 28
10. A.M. Tsimogianni, I. Andrianakis, A. Betrosian, and et al. Cardiac arrest provoked by itraconazole and amiodarone interaction: a case report J Med Case Rep 5 2011 333
11. S. Harder, and P. Thurmann Clinically important drug interactions with anticoagulants. An update Clin Pharmacokinet 30 1996 416 444